Purpose. To investigate the efficacy and safety of 360° selective laser trabeculoplasty (SLT) on medically uncontrolled open-angle glaucoma (OAG) and to evaluate the effects of antiglaucomatous medications on the results of therapy. Materials and Methods. The medical records of 62 eyes of 51 patients with OAG, which did not reach the targeted intraocular pressure (IOP) with maximum antiglaucomatous medical therapy, were retrospectively reviewed. Results. A statistically significant decrease was observed in the mean baseline IOP at 1, 3, 6, and 12 months of followup ( ). The success rate was 64.5% in all of the patients. The success rates did not vary significantly by taking 1, 2, 3, or 4 medications with the rates of 63.6%, 71.4%, 64.2%, and 58.3% ( ). The success rate of eyes on medication more or less than 6 months was 62.5% or 66.7%, respectively ( ). There was a positive correlation between mean baseline IOP and mean reduction in IOP from baseline ( , ). Conclusion. Application of 360° of SLT provided an effective and safe IOP reduction in medically uncontrolled OAG. Baseline IOP was found to be the most important factor in the efficacy of therapy. 1. Introduction Several studies have corroborated the efficacy and safety of selective laser trabeculoplasty (SLT) since its first description in 1995 by Latina and Park [1]. Selective laser trabeculoplasty, which uses a 532？nm frequency-doubled, Q-switched Nd:YAG laser, is thought to selectively stimulate the pigmented trabecular meshwork cells and thus facilitate improved aqueous outflow in open-angle glaucoma (OAG) [2]. A synthesis of previous data suggests that SLT is effective at every stage of treatment for OAG. Selective laser therapy can be used as a first-line therapy, alternative to medical therapy, or as an adjunctive therapy to topical glaucoma drops [3, 4]. Although success rates and levels of reported IOP reduction vary between studies, a great number of studies show that it is a safe procedure with low complication rates [5–7]. This heterogeneity could be explained by differences in the samples, outcomes, and treatment protocols such as power, spot numbers, and the degree of angle treated. The aims of this study were to investigate the safety and efficacy of 360° SLT application in patients with OAG who were not well controlled with maximal medical therapy and also to evaluate the factors that could influence the results including the number and type of antiglaucomatous medications, duration of medical therapy, and baseline IOP. 2. Materials and Methods This was a retrospective chart review
References
[1]
M. A. Latina and C. Park, “Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions,” Experimental Eye Research, vol. 60, no. 4, pp. 359–371, 1995.
[2]
J. D. Stein and P. Challa, “Mechanisms of action and efficacy of argon laser trabeculoplasty and selective laser trabeculoplasty,” Current Opinion in Ophthalmology, vol. 18, no. 2, pp. 140–145, 2007.
[3]
I. McIlraith, M. Strasfeld, G. Colev, and C. M. L. Hutnik, “Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma,” Journal of Glaucoma, vol. 15, no. 2, pp. 124–130, 2006.
[4]
J. S. M. Lai, J. K. H. Chua, C. C. Y. Tham, and D. S. C. Lam, “Five-year follow up of selective laser trabeculoplasty in Chinese eyes,” Clinical and Experimental Ophthalmology, vol. 32, no. 4, pp. 368–372, 2004.
[5]
M. S. Juzych, V. Chopra, M. R. Banitt et al., “Comparison of long-term outcomes of selective laser trabeculoplasty versus argon laser trabeculoplasty in open-angle glaucoma,” Ophthalmology, vol. 111, no. 10, pp. 1853–1859, 2004.
[6]
M. Ayala and E. Chen, “Comparison of selective laser trabeculoplasty (SLT) in primary open angle glaucoma and pseudoexfoliation glaucoma,” Clinical Ophthalmology, vol. 5, pp. 1469–1473, 2011.
[7]
J. Song, P. P. Lee, D. L. Epstein et al., “High failure rate associated with 180 degrees selective laser trabeculoplasty,” Journal of Glaucoma, vol. 14, no. 5, pp. 400–408, 2005.
[8]
T. Gra？ner, “Intraocular pressure response to selective laser trabeculoplasty in the treatment of primary open-angle glaucoma,” Ophthalmologica, vol. 215, no. 4, pp. 267–270, 2001.
[9]
T. Gra？ner, “Intraocular pressure response of capsular glaucoma and primary open-angle glaucoma to selective Nd:YAG laser trabeculoplasty: a prospective, comparative clinical trial,” European Journal of Ophthalmology, vol. 12, no. 4, pp. 287–292, 2002.
[10]
N. Kara, C. Altan, B. Satana et al., “Comparison of selective laser trabeculoplasty success in patients treated with either prostaglandin or timolol/dorzolamide fixed combination,” Journal of Ocular Pharmacology and Therapeutics, vol. 27, no. 4, pp. 339–342, 2011.
[11]
D. Singh, M. A. Coote, F. O'Hare et al., “Topical prostaglandin analogues do not affect selective laser trabeculoplasty outcomes,” Eye, vol. 23, no. 12, pp. 2194–2199, 2009.
[12]
K. Kano, Y. Kuwayama, S. Mizoue, and N. Ito, “Clinical results of selective laser trabeculoplasty,” Nippon Ganka Gakkai Zasshi, vol. 103, no. 8, pp. 612–616, 1999.
[13]
E. Chen, S. Golchin, and S. Blomdahl, “A comparison between 90 degrees and 180 degrees selective laser trabeculoplasty,” Journal of Glaucoma, vol. 13, no. 1, pp. 62–65, 2004.
[14]
A. J. Mao, X. J. Pan, I. McIlraith, M. Strasfeld, G. Colev, and C. Hutnik, “Development of a prediction rule to estimate the probability of acceptable intraocular pressure reduction after selective laser trabeculoplasty in open-angle glaucoma and ocular hypertension,” Journal of Glaucoma, vol. 17, no. 6, pp. 449–454, 2008.
[15]
J. Song, P. P. Lee, D. L. Epstein et al., “High failure rate associated with 180° selective laser trabeculoplasty,” Journal of Glaucoma, vol. 14, no. 5, pp. 400–408, 2005.
[16]
T. Realini, “Selective laser trabeculoplasty: a review,” Journal of Glaucoma, vol. 17, no. 6, pp. 497–502, 2008.
[17]
R. Sihota, “Lasers in primary open angle glaucoma,” Indian Journal of Ophthalmology, vol. 59, supplement 1, pp. S114–S117, 2011.
[18]
S. Melamed, G. J. Ben Simon, and H. Levkovitch-Verbin, “Selective laser trabeculoplasty as primary treatment for open-angle glaucoma: a prospective, nonrandomized pilot study,” Archives of Ophthalmology, vol. 121, no. 7, pp. 957–960, 2003.
[19]
T. Gra？ner, D. Pahor, and B. Gra？ner, “Efficacy of selective laser trabeculoplasty in the treatment of primary open-angle glaucoma,” Klinische Monatsbl？tter für Augenheilkunde, vol. 220, no. 12, pp. 848–852, 2003.
[20]
B. Cvenkel, “One-year follow-up of selective laser trabeculoplasty in open-angle glaucoma,” Ophthalmologica, vol. 218, no. 1, pp. 20–25, 2004.
[21]
M. Nagar, A. Ogunyomade, D. P. S. O'Brart, F. Howes, and J. Marshall, “A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma,” British Journal of Ophthalmology, vol. 89, no. 11, pp. 1413–1417, 2005.
